JP2006519842A - アザスピラン化合物による癌治療法 - Google Patents

アザスピラン化合物による癌治療法 Download PDF

Info

Publication number
JP2006519842A
JP2006519842A JP2006506985A JP2006506985A JP2006519842A JP 2006519842 A JP2006519842 A JP 2006519842A JP 2006506985 A JP2006506985 A JP 2006506985A JP 2006506985 A JP2006506985 A JP 2006506985A JP 2006519842 A JP2006519842 A JP 2006519842A
Authority
JP
Japan
Prior art keywords
cancer
hydrogen atom
unbranched
carbon atoms
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006506985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519842A5 (https=
Inventor
ドナルド・エイチ・ピッカー
ジェフリー・ダブリュー・ヘンソン
サイモン・フリッカー
クンワル・シャイルバイ
ゲイリー・エス・ジェイコブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Callisto Pharmaceuticals Inc
Original Assignee
Callisto Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Callisto Pharmaceuticals Inc filed Critical Callisto Pharmaceuticals Inc
Publication of JP2006519842A publication Critical patent/JP2006519842A/ja
Publication of JP2006519842A5 publication Critical patent/JP2006519842A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2006506985A 2003-03-10 2004-03-10 アザスピラン化合物による癌治療法 Withdrawn JP2006519842A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45295103P 2003-03-10 2003-03-10
US47492903P 2003-06-03 2003-06-03
PCT/US2004/007144 WO2004080408A2 (en) 2003-03-10 2004-03-10 Method of treating cancer with azaspirane compositions

Publications (2)

Publication Number Publication Date
JP2006519842A true JP2006519842A (ja) 2006-08-31
JP2006519842A5 JP2006519842A5 (https=) 2007-06-14

Family

ID=32994468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006506985A Withdrawn JP2006519842A (ja) 2003-03-10 2004-03-10 アザスピラン化合物による癌治療法

Country Status (7)

Country Link
US (2) US20050250801A1 (https=)
EP (1) EP1610806A4 (https=)
JP (1) JP2006519842A (https=)
CA (1) CA2518357A1 (https=)
MX (1) MXPA05009708A (https=)
TW (1) TW200505438A (https=)
WO (1) WO2004080408A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447281B1 (en) * 2005-03-24 2015-12-16 ThromboGenics N.V. Novel anti-PLGF antibody
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
EP2192904B1 (en) * 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2543812B1 (en) * 2011-07-08 2014-11-05 Welltec A/S Downhole hydraulic pump

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US6051596A (en) * 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
SG43383A1 (en) * 1995-07-13 1997-10-17 Smithkline Beecham Corp N n-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dimaleate
WO1997002820A1 (en) * 1995-07-13 1997-01-30 Anormed Inc. N,n-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate
BR9709007A (pt) * 1996-05-17 2000-01-04 Anormed Inc Uso de azaspirano substituìdo no tratamento da asma.

Also Published As

Publication number Publication date
MXPA05009708A (es) 2006-05-25
EP1610806A2 (en) 2006-01-04
WO2004080408A3 (en) 2004-12-09
US20070015780A1 (en) 2007-01-18
TW200505438A (en) 2005-02-16
EP1610806A4 (en) 2006-04-19
CA2518357A1 (en) 2004-09-23
US20050250801A1 (en) 2005-11-10
WO2004080408A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
CA2919996A1 (en) Methods for the treatment of solid tumors
JP2021046418A (ja) コルテキソロン１７α−バレレートを含む腫瘍治療に用いるための組成物
PH12015500246B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2006519842A (ja) アザスピラン化合物による癌治療法
CA2404087A1 (en) Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
JP2006519842A5 (https=)
CA2238283C (en) Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
US20090259054A1 (en) Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration
KR20180129795A (ko) 렌바티닙 및 에베롤리무스를 사용한 신세포 암종의 치료
Kauntz Cellular and molecular targets of silibinin, a natural flavonoid, in colorectal cancer prevention and therapy
Murphy et al. Human pancreatic acinar cells have functional cholecystokinin receptors
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
Keller et al. 13C-MIXED TRIGLYCERIDE BREATH TEST (13C-MTG) DEMONSTRATES SUPERIORITY OF ENTERIC COATED MONOLITHIC ENZYME PREPARATION OVER PLACEBO: A MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL
Zarantonello et al. Volatile organic compounds in breath in patients with pancreatic tumor. A preliminary case-control prospective study
Funakoshi et al. Final results of a phase II study of S-1 in patients with metastatic pancreatic cancer
Patel et al. Tetracycline-inducible pancreatic cancer cell lines
Schloithe et al. Chemosensitive afferent activity in the isolated rat pancreas
Schmitz-Winnenthal et al. Selective expression of tumor associated antigens by samples derived from human pancreatic cancer
Pour Diabetes is not a predisposing factor for pancreatic cancer-new evidence
Masamune et al. NADPH oxidase plays a key role in the activation of pancreatic stellate cells
Ishiwata et al. Expression and role of type 1 and 2 isoforms of ubiquitin-specific protease 14 in human pancreatic cancer
Neri et al. Timing of the endoscopic sphincterotomy (ES) and of the videolaparocholecystectomy (VLC) in the acute biliary pancreatitis
Yamamoto et al. PANCREATIC FIBROSIS INCREASED AFTER DISCONTINUATION OF PRAVASTATIN TREATMENT IN OLETF RAT
Papachristou et al. Minimal access, endoscopic drainage/debridement of walled-off necrosis after necrotizing pancreatitis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070423

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090818